Biotech: Page 34
-
Thomas Lohnes via Getty Images
BioNTech partners with Autolus to boost cell therapy manufacturing
The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, give it licensing options and access to supply infrastructure.
By Kristin Jensen • Feb. 8, 2024 -
Getty Images
Kyverna IPO adds to biotech momentum with $319M fundraise
The company, a leading developer of cell therapies for autoimmune diseases, is the fifth drug startup to go public in 2024. All raised at least $100 million.
By Ben Fidler • Feb. 7, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
BridgeBio sells partial rights to dwarfism drug for $100M
The deal hands Kyowa Kirin rights in Japan to the drug, which is emerging as a potential rival to BioMarin’s marketed medicine Voxzogo.
By Delilah Alvarado • Feb. 7, 2024 -
Permission granted by Scion Life Sciences
Venture firm Scion Life Sciences launches with $310M to back new biotechs
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said co-founder Aaron Kantoff.
By Gwendolyn Wu • Feb. 7, 2024 -
Permission granted by Khosla Ventures
Q&AKhosla Ventures’ Alex Morgan on biotech’s challenges and solving drug delivery
The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.
By Gwendolyn Wu • Feb. 6, 2024 -
Valneva sells regulatory ‘fast pass’ for $103M
The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.
By Delilah Alvarado • Feb. 5, 2024 -
Getty Images
Arch, a prolific biotech creator, is raising $3B for startup investing
A regulatory filing shows the firm is putting together a new multibillion-dollar fund, roughly two years after raising a similar amount.
By Ben Fidler • Feb. 2, 2024 -
Spencer Platt via Getty Images
Brain drug developer Alto Neuroscience prices $129M IPO
The biotech was joined by Fractyl Health in pricing an IPO Thursday evening, adding to last month’s stock offerings from CG Oncology and Arrivent BioPharma.
By Gwendolyn Wu • Feb. 2, 2024 -
Michael M. Santiago via Getty Images
Avrobio’s road ends in reverse merger with Tim Springer-backed startup
The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.
By Kristin Jensen • Jan. 31, 2024 -
Getty Images
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.
By Ben Fidler • Jan. 30, 2024 -
Courtesy of Regeneron Pharmaceuticals
Regeneron to acquire 2seventy’s cell therapy pipeline
About 150 of the smaller company's employees will also transition to Regeneron, which is setting up a new cellular medicines research and development unit.
By Ned Pagliarulo • Jan. 30, 2024 -
Permission granted by Vertex Pharmaceuticals
Non-opioid drug from Vertex cuts pain in major trial tests
While the overall results were positive, the drug fell short in both studies on a secondary goal comparing it to a widely prescribed opioid.
By Ned Pagliarulo • Jan. 30, 2024 -
Getty Images
Deep Dive // State of PlayCAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.
By Ben Fidler • Jan. 30, 2024 -
Carl Court via Getty Images
PTC Duchenne drug approval set to be revoked in Europe
The EMA’s drugs committee again recommended rescinding an OK for Translarna, which was cleared in 2014 despite questions about its benefit.
By Ben Fidler • Jan. 26, 2024 -
Michael M. Santiago via Getty Images
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO
The company is developing an oral alternative to J&J’s lung cancer medicine Rybrevant, and adds to a trend of late-stage drugmakers finding investor demand on Wall Street.
By Ben Fidler • Jan. 25, 2024 -
Permission granted by Bristol-Myers Squibb
RayzeBio drew other pharma interest before Bristol Myers deal
Two “global biopharmaceutical companies” made bids to buy the radiopharma specialist, but lost out to Bristol Myers, which negotiated aggressively to secure a $4.1 billion buyout.
By Ned Pagliarulo • Jan. 25, 2024 -
Getty Images
BenevolentAI appoints former Bayer R&D chief as CEO
The pharma veteran will take over the AI-focused biotech after a year that included a restructuring, job cuts and the resignation of its CFO.
By Kristin Jensen • Jan. 25, 2024 -
Getty Images
CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech
The sector’s first IPO of 2024 could be a positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
By Gwendolyn Wu • Jan. 24, 2024 -
Getty Images
Novo strikes another obesity drug deal
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight loss drugs.
By Kristin Jensen • Jan. 24, 2024 -
Courtesy of Sanofi
Sanofi to buy Inhibrx in deal worth up to $2.2B
The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.
By Ned Pagliarulo • Jan. 23, 2024 -
Getty Images
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
J&J and Bristol Myers joined the latest funding round for the startup, which was led by the newly launched Mirae Asset Capital Life Science.
By Gwendolyn Wu • Jan. 23, 2024 -
Courtesy of Coherus Biosciences
Coherus sells Lucentis biosimilar to Sandoz for $170M
The divestment, which includes sales and reimbursement staff, is part of Coherus’ plan to shift resources toward its R&D work in oncology.
By Delilah Alvarado • Jan. 22, 2024 -
Getty Images
Ionis says rare disease drug succeeds in late-stage HAE study
The medicine, called donidalorsen, reduced hereditary angioedema-related attacks in the Phase 3 trial. Several competing options to it are already available or in advanced testing, however.
By Ben Fidler • Jan. 22, 2024 -
Getty Images
Ikena Oncology to lay off 35% of staff
The cancer drugmaker is one of about a dozen biotechs that have announced workforce reductions so far in 2024.
By Delilah Alvarado • Jan. 19, 2024 -
Getty Images
A South Korean investment firm starts first US biotech fund
The $50 million fund, called Mirae Asset Capital Life Science, will back biotechnology companies from seed to Series C rounds.
By Gwendolyn Wu • Jan. 18, 2024
Previous
